


Application No. 10/780,103  
Amendment Dated December 20, 2005  
Reply to Office Action of September 20, 2005

**Listing of Claims:**

1-48. (Canceled)

49. (Previously Presented) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-1 $\alpha$ ,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D<sub>3</sub> having the structure



50-53. (Canceled)

54. (Previously Presented) The method of claim 49 wherein the compound is administered orally.

55. (Previously Presented) The method of claim 49 wherein the compound is administered parenterally.


56. (Previously Presented) The method of claim 49 wherein the compound is administered transdermally.

57. (Previously Presented) The method of claim 49 wherein said effective amount comprises about 0.01 $\mu$ g/day to about 100 $\mu$ g/day of 20(S)-1 $\alpha$ ,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D<sub>3</sub>.

58. (Previously Presented) The method of claim 49 wherein said effective amount comprises about 0.1 $\mu$ g/day to about 50 $\mu$ g/day of 20(S)-1 $\alpha$ ,25-dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D<sub>3</sub>.

Application No. 10/780,103  
Amendment Dated December 20, 2005  
Reply to Office Action of September 20, 2005

59. (Previously Presented) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D<sub>3</sub> having the structure



60-63. (Canceled)

64. (Previously Presented) The method of claim 59 wherein the compound is administered orally.

65. (Previously Presented) The method of claim 59 wherein the compound is administered parenterally.

66. (Previously Presented) The method of claim 59 wherein the compound is administered transdermally.


67. (Previously Presented) The method of claim 59 wherein said effective amount comprises about 0.01 µg/day to about 100 µg/day of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D<sub>3</sub>.

68. (Previously Presented) The method of claim 59 wherein said effective amount comprises about 0.1 µg/day to about 50 µg/day of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D<sub>3</sub>.

69. (Previously Presented) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer

Application No. 10/780,103  
 Amendment Dated December 20, 2005  
 Reply to Office Action of September 20, 2005

comprising administering to a patient with said disease an effective amount of 20(S)-1 $\alpha$ ,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D<sub>3</sub> having the structure



70-73. (Canceled)

74. (Previously Presented) The method of claim 69 wherein the compound is administered orally.

75. (Previously Presented) The method of claim 69 wherein the compound is administered parenterally.


76. (Previously Presented) The method of claim 69 wherein the compound is administered transdermally.

77. (Previously Presented) The method of claim 69 wherein said effective amount comprises about 0.01 $\mu$ g/day to about 100 $\mu$ g/day of 20(S)-1 $\alpha$ ,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D<sub>3</sub>.

78. (Previously Presented) The method of claim 69 wherein said effective amount comprises about 0.1 $\mu$ g/day to about 50 $\mu$ g/day of 20(S)-1 $\alpha$ ,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D<sub>3</sub>.

79. (Previously Presented) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene-1 $\alpha$ -hydroxy-2-methylene-24-dehydro-19-norvitamin D<sub>3</sub> having the structure

Application No. 10/780,103  
Amendment Dated December 20, 2005  
Reply to Office Action of September 20, 2005



80-83. (Canceled)

84. (Previously Presented) The method of claim 79 wherein the compound is administered orally.

85. (Previously Presented) The method of claim 79 wherein the compound is administered parenterally.

86. (Previously Presented) The method of claim 79 wherein the compound is administered transdermally.

87. (Previously Presented) The method of claim 79 wherein said effective amount comprises about 0.01 µg/day to about 100 µg/day of 20(S)-26,27-dimethylene-1α-hydroxy-2-methylene-24-dehydro-19-norvitamin D<sub>3</sub>.

88. (Previously Presented) The method of claim 79 wherein said effective amount comprises about 0.1 µg/day to about 50 µg/day of 20(S)-26,27-dimethyl-1α-hydroxy-2-methylene-24-dehydro-19-norvitamin D<sub>3</sub>.